1. 2000
2. Published

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Jan 2000, In: Value in Health. 3, 5, p. 373

   Research output: Contribution to journal › Article › peer-review

3. Published

   Pragmatic trials - design features and implications for clinical decision making

   Hughes, D., Urdahl, H., Hughes, D. A. & Freemantle, N., 1 Aug 2000.

   Research output: Contribution to conference › Paper

4. Published

   The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Nov 2000.

   Research output: Contribution to conference › Paper

5. 2001
6. Published

   A review of economic models for second-line chemotherapy in the management of advanced, metastatic breast cancer.

   Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

   Research output: Book/Report › Commissioned report

7. Published

   Accounting for non-compliance in pharmacoeconomic evaluations.

   Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 12, p. 1185-1197

   Research output: Contribution to journal › Article › peer-review

8. Published

   Economic evaluations during early (Phase II) drug development: A role for clinical trial simulations.

   Hughes, D., Hughes, D. A. & Walley, T., 1 Jan 2001, In: Pharmacoeconomics. 19, 11, p. 1069-1077

   Research output: Contribution to journal › Article › peer-review

9. Published

   Pharmacokinetic-Pharmacodynamic modelling of Lapdap (CPG-DDS) combination.

   Hughes, D., Hughes, D. A., Watkins, B. & Winstanley, P., 1 Jan 2001, 2001 ed. Unknown.

   Research output: Book/Report › Commissioned report

10. Published

    The influence of non-compliance on the effectiveness and cost-effectiveness of drug therapies.

    Hughes, D. & Hughes, D. A., 1 Jan 2001, 2001 ed. Unknown.

    Research output: Book/Report › Commissioned report

11. Published

    Impact of non-compliance on the cost-effectiveness of statin therapy

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Sept 2001, In: Value in Health. 4, 6, p. 489

    Research output: Contribution to journal › Article › peer-review

12. Published

    Pharmacometric analysis of duration of drug action: implications for improved forgiveness to medication non-compliance

    Hughes, D., Hughes, D. A. & Walley, T., 1 Sept 2001.

    Research output: Contribution to conference › Paper

13. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Oct 2001.

    Research output: Contribution to conference › Paper

14. Published

    The impact of non-compliance on the cost-effectiveness of pharmaceuticals: A review of the literature.

    Hughes, D., Hughes, D. A., Bagust, A., Haycox, A. & Walley, T., 1 Oct 2001, In: Health Economics. 10, 7, p. 601-615

    Research output: Contribution to journal › Article › peer-review

15. Published

    Impact of non-compliance on the clinical and cost-effectiveness of statins

    Hughes, D. & Hughes, D. A., 1 Nov 2001.

    Research output: Contribution to conference › Paper

16. 2002
17. Published

    Impact of non-compliance on the therapeutic coverage of oxybutynin – comparison of once- and twice-daily oral formulations.

    Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

    Research output: Book/Report › Commissioned report

18. Published

    Impact of non-compliance on the therapeutic coverage of risperidone – comparison of long acting injectible with oral formulations.

    Hughes, D. & Hughes, D. A., 1 Jan 2002, 2002 ed. Unknown.

    Research output: Book/Report › Commissioned report

19. Published

    From efficacy to cost-effectiveness: accounting for non-compliance in pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 May 2002.

    Research output: Contribution to conference › Paper

20. Published

    Economic impact of poor compliance with pharmaceuticals.

    Hughes, D. & Hughes, D. A., 1 Aug 2002, In: Expert Review of Pharmacoeconomics and Outcomes Research. 2, 4, p. 327-335

    Research output: Contribution to journal › Article › peer-review

21. Published

    Accurate and practical dosing of African populations using a height, weight and age model designed for lapdap

    Hughes, D., Hughes, D. A. & Bagust, A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

22. Published

    Economic evaluation during early (phase II) trials

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

23. Published

    Impact of non-compliance on the cost-effectiveness of pharmaceuticals

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

24. Published

    Patient compliance and pharmacoeconomics

    Hughes, D. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

25. Published

    The population pharmacokinetics of lapdap

    Hughes, D., Ward, S., Simpson, J., Aarons, L., Szwandt, S. & Hughes, D. A., 1 Nov 2002.

    Research output: Contribution to conference › Paper

26. 2003
27. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 May 2003.

    Research output: Contribution to conference › Paper

28. Published

    Abacavir hypersensitivity: Is pre-prescription genotyping cost-effective?

    Hughes, D. & Hughes, D. A., 1 Jun 2003.

    Research output: Contribution to conference › Paper

29. Published

    Predicting "real world" effectiveness by integrating adherence with pharmacodynamic modelling.

    Hughes, D., Hughes, D. A. & Walley, T., 1 Jul 2003, In: Clinical Pharmacology and Therapeutics. 74, 1, p. 1-8

    Research output: Contribution to journal › Article › peer-review